ACE and hydrops fetalis: Angiotensin-converting enzyme inhibitors (ACEis) are strongly recommended as the first-line therapy for patients with HFrEF, given their demonstrated efficacy in reducing cardiovascular mortality and hospitalization for HF on a large-scale basis [2,64].